EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC 4.0

Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double‐blind, parallel‐controlled clinical trial

Huihui Bao, Xiao Huang iD, Ping Li, Changsheng Sheng iD, Jin Zhang, Zhirong Wang, Demin Song, Lihua Hu, Congcong Ding, Zaihua Cheng, Chen Yao, Guangliang Chen und 7 weitere

The Journal of Clinical Hypertension · 2023

DOI: 10.1111/jch.14697 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2023. Verfasst von Huihui Bao und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Hypertension, Hyperhomocysteinemia, Stroke. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke. The China stroke primary prevention trial showed that combining 0.8 mg folic acid (FA) with angiotensin‐converting enzyme inhibitor (ACEI) can effectively lower plasma total homocysteine (tHcy) and blood pressure (BP); and reduce first stroke risk by additional 21% compared to ACEI alone. However, intolerance to ACEI is common in Asians and amlodipine can be alternative. This is a multicenter, randomized, double‐blind, parallel‐controlled clinical trial (RCT) which evaluated whether amlodipine combined with FA is more efficacious than amlodipine alone in lowering tHcy and BP among Chinese hypertensive with hyperhomocysteinemia and intolerance to ACEI. 351 Eligible patients were randomly assigned by 1:1:1 ratio to receive amlodipine‐FA tablet daily (amlodipine 5 mg/FA 0.4 mg, A group); amlodipine 5 mg/FA 0.8 mg tablet daily (B group); amlodipine 5 mg daily (C group, control group). Follow‐up was conducted at 2, 4, 6, and 8 weeks. The primary outcome was efficacy of lowering both tHcy and BP at the end of 8‐week treatment. Compared with C group, A group had a significantly higher rate of lowering both tHcy and BP (23.3% vs. 6.0%; Odds Ratio [OR], 8.68; 95% CI, 3.04‐24.78, P < .001); B group also had a higher rate of lowering both tHcy and BP (20.3% vs. 6.0%; OR: 5.90; 95% CI, 2.11‐16.47, P < .001). This RCT showed amlodipine combined with FA compared with amlodipine alone, each had significantly higher efficacy of lowering both tHcy and BP. No difference was found in BP‐lowering and occurrence of adverse events between the three groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionHyperhomocysteinemiaStrokeHumansFolic AcidAngiotensin-Converting Enzyme InhibitorsAmlodipineBlood PressureDouble-Blind MethodHomocysteineTreatment Outcome

Stichwörter der Autor:innen

amlodipine-folic acidblood pressurehypertension with hyperhomocysteinemiarandomized clinical trialtotal homocysteine

Substanzen

Folic AcidAngiotensin-Converting Enzyme InhibitorsAmlodipineHomocysteine

Autor:innen und Institutionen

  • Department of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
  • The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Affiliated Hospital of Xuzhou Medical College, Xuzhou, China.
  • Anqing Municipal Hospital, Anqing, China.
  • Peking University Clinical Research Institute, Peking University Health Science Center, Beijing, China.
  • College of Integrated Chinese and Western Medicine, Anhui University of Chinese Medicine, Hefei, China.

ORCID-Profile: Xiao Huang, Changsheng Sheng, Xianhui Qin, Yong Huo

Förderung

  • National Basic Research Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Bao, H., Huang, X., Li, P., Sheng, C., Zhang, J., Wang, Z., Song, D., Hu, L., Ding, C., Cheng, Z., Yao, C., Chen, G., Cui, Y., Qin, X., Tang, G., Wang, X., Huo, Y., Cheng, X., & Wang, J. (2023). Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double‐blind, parallel‐controlled clinical trial. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.14697

Vancouver

Bao H, Huang X, Li P, Sheng C, Zhang J, Wang Z, et al. Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double‐blind, parallel‐controlled clinical trial. The Journal of Clinical Hypertension. 2023. doi:10.1111/jch.14697

BibTeX
@article{Bao2023,
  author = {Bao, Huihui and Huang, Xiao and Li, Ping and Sheng, Changsheng and Zhang, Jin and Wang, Zhirong and Song, Demin and Hu, Lihua and Ding, Congcong and Cheng, Zaihua and Yao, Chen and Chen, Guangliang and Cui, Yimin and Qin, Xianhui and Tang, Genfu and Wang, Xiaobin and Huo, Yong and Cheng, Xiaoshu and Wang, Jiguang},
  title = {Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double‐blind, parallel‐controlled clinical trial},
  journal = {The Journal of Clinical Hypertension},
  year = {2023},
  doi = {10.1111/jch.14697}
}
Kostenlos starten →